vs
嘉楠科技（CAN）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
Day One Biopharmaceuticals, Inc.的季度营收约是嘉楠科技的1.9倍（$39.8M vs $20.8M），嘉楠科技净利率更高（-18.4% vs -49.6%，领先31.1%）
嘉楠科技（Canaan Inc.），也以嘉楠耘智之名开展业务，总部位于新加坡，是一家成立于2013年的计算机硬件厂商，由张楠赓创立，核心产品为比特币挖矿专用的区块链服务器与ASIC微处理器，在加密货币挖矿硬件领域拥有深厚技术积累。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
CAN vs DAWN — 直观对比
营收规模更大
DAWN
是对方的1.9倍
$20.8M
净利率更高
CAN
高出31.1%
-49.6%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.8M | $39.8M |
| 净利润 | $-3.8M | $-19.7M |
| 毛利率 | 99.9% | — |
| 营业利润率 | -15.9% | -60.9% |
| 净利率 | -18.4% | -49.6% |
| 营收同比 | — | -57.6% |
| 净利润同比 | — | -153.3% |
| 每股收益（稀释后） | $-0.05 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CANDAWN
| Q4 25 | $20.8M | — | ||
| Q3 25 | $13.8M | $39.8M | ||
| Q2 25 | $11.4M | $33.9M | ||
| Q1 25 | — | $30.8M | ||
| Q3 24 | $10.2M | $93.8M | ||
| Q2 24 | $4.8M | — | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 |
净利润CANDAWN
| Q4 25 | $-3.8M | — | ||
| Q3 25 | $-1.5M | $-19.7M | ||
| Q2 25 | $-11.9M | $-30.3M | ||
| Q1 25 | — | $-36.0M | ||
| Q3 24 | $-10.4M | $37.0M | ||
| Q2 24 | $-5.4M | — | ||
| Q1 24 | — | $-62.4M | ||
| Q3 23 | — | $-46.1M |
毛利率CANDAWN
| Q4 25 | 99.9% | — | ||
| Q3 25 | 99.9% | — | ||
| Q2 25 | 99.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
营业利润率CANDAWN
| Q4 25 | -15.9% | — | ||
| Q3 25 | -27.0% | -60.9% | ||
| Q2 25 | -45.5% | -103.1% | ||
| Q1 25 | — | -133.5% | ||
| Q3 24 | -77.2% | 31.6% | ||
| Q2 24 | -193.9% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
净利率CANDAWN
| Q4 25 | -18.4% | — | ||
| Q3 25 | -11.0% | -49.6% | ||
| Q2 25 | -104.4% | -89.4% | ||
| Q1 25 | — | -117.0% | ||
| Q3 24 | -102.7% | 39.5% | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
每股收益（稀释后）CANDAWN
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.02 | $-0.19 | ||
| Q2 25 | $-0.25 | $-0.29 | ||
| Q1 25 | — | $-0.35 | ||
| Q3 24 | — | $0.38 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-0.72 | ||
| Q3 23 | — | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $451.6M |
| 总债务越低越好 | $6.2M | — |
| 股东权益账面价值 | $52.4M | $450.9M |
| 总资产 | $92.5M | $513.8M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | $451.6M | ||
| Q2 25 | — | $453.1M | ||
| Q1 25 | — | $473.0M | ||
| Q3 24 | — | $558.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $317.9M | ||
| Q3 23 | — | $405.5M |
总债务CANDAWN
| Q4 25 | $6.2M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
股东权益CANDAWN
| Q4 25 | $52.4M | — | ||
| Q3 25 | $44.7M | $450.9M | ||
| Q2 25 | $33.8M | $460.8M | ||
| Q1 25 | — | $479.5M | ||
| Q3 24 | $43.6M | $555.5M | ||
| Q2 24 | $56.8M | — | ||
| Q1 24 | — | $296.8M | ||
| Q3 23 | — | $389.6M |
总资产CANDAWN
| Q4 25 | $92.5M | — | ||
| Q3 25 | $81.7M | $513.8M | ||
| Q2 25 | $78.0M | $519.0M | ||
| Q1 25 | — | $534.4M | ||
| Q3 24 | $69.3M | $600.8M | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | — | $326.6M | ||
| Q3 23 | — | $414.2M |
负债/权益比CANDAWN
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.0M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-49.7M | ||
| Q3 23 | — | $-37.1M |
自由现金流CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.3M | ||
| Q3 24 | — | $50.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-37.1M |
自由现金流率CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -192.8% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
资本支出强度CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
现金转化率CANDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAN
暂无分部数据
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
